Investor Alert

Regeneron Pharmaceuticals Inc.



After Hours

 --Quotes are delayed by 20 min

Jan 28, 2022, 7:49 p.m.





-2.76 -0.44%


Volume 21,756

Quotes are delayed by 20 min


Previous close

$ 608.72

$ 624.92


+16.20 +2.66%

Day low

Day high




52 week low

52 week high




Annual Financials for Regeneron Pharmaceuticals Inc.

Fiscal year is January-December. All values USD millions. 20162017201820192020 5-year trend
Sales/Revenue 4.86B5.87B6.71B6.56B8.5B
Cost of Goods Sold (COGS) incl. D&A 404.44M542.53M582.3M975.4M1.36B
COGS excluding D&A 299.69M397.06M434.1M765.1M1.12B
Depreciation & Amortization Expense 104.75M145.47M148.2M210.3M235.9M
Depreciation 104.75M145.47M148.2M210.3M235.9M
Amortization of Intangibles -----
Gross Income 4.46B5.33B6.13B5.58B7.14B
20162017201820192020 5-year trend
SG&A Expense 3.13B3.25B3.59B3.58B3.85B
Research & Development 1.95B1.93B2.04B2.24B2.5B
Other SG&A 1.18B1.32B1.56B1.34B1.35B
Other Operating Expense ---(209.2M)(280.4M)
Unusual Expense 9.8M30.1M41.9M(118.3M)(196M)
EBIT after Unusual Expense 1.32B2.05B2.49B118.3M3.77B
Non Operating Income/Expense 16.07M54.14M89.2M131.2M94.7M
Non-Operating Interest Income -----
Equity in Affiliates (Pretax) -----
Interest Expense 7.2M25.12M28.2M30.2M56.9M
Gross Interest Expense 7.2M25.12M28.2M30.2M56.9M
Interest Capitalized -----
Pretax Income 1.33B2.08B2.55B2.43B3.81B
Income Tax 434.29M880M109.1M313.3M297.2M
Income Tax - Current Domestic 795.73M556.16M228.5M446.5M200.2M
Income Tax - Current Foreign (1.36M)4.83M20.6M(2.6M)21.4M
Income Tax - Deferred Domestic (363.94M)315.81M685.7M(133.7M)107M
Income Tax - Deferred Foreign 3.86M3.2M(825.7M)3.1M(31.4M)
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income 895.52M1.2B2.44B2.12B3.51B
Minority Interest Expense -----
Net Income 895.52M1.2B2.44B2.12B3.51B
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries 895.52M1.2B2.44B2.12B3.51B
Preferred Dividends -----
Net Income Available to Common 895.52M1.2B2.44B2.12B3.51B
EPS (Basic) 8.5511.2722.6519.3832.65
Basic Shares Outstanding 104.72M106.34M107.9M109.2M107.6M
EPS (Diluted) 7.7010.3421.2918.4630.52
Diluted Shares Outstanding 116.37M115.95M114.8M114.6M115.1M
EBITDA 1.44B2.23B2.68B2.42B3.81B
Link to MarketWatch's Slice.